[Edaily Reporter Kwon Oh Seok ] Macquarie Securities announced on the 4th that it has designated BHI Co., LTD.(083650)as a top pick within the sector, alongside DOOSAN ENERBILITY and HyundaiEngineering&Construction, as the U.S. nuclear power market moves beyond policy expectations into the actual order-winning phase. The firm maintained its “Buy” rating and set a target price of 107,000 won. BHI Co., LTD. logo. (Photo courtesy of BHI Co., LTD.) Lee Jae-seo, an analyst at Macquarie Securities, stated in a report titled “Korea Nuclear: From Narrative to Orders” “The U.S. nuclear power market is entering a substantive order cycle, not merely a policy cycle,” and analyzed that “the period from the second half of 2026 to the first half of 2027 will be a critical turning point where momentum in nuclear power investment shifts from expectations to actual orders.” The analyst noted, “The U.S. Department of Energy’s (DOE) $17.5 billion nuclear power supply chain loan program will serve as a key link connecting the industry’s vision with actual procurement,” and assessed that “since this program can provide funding for long-lead-time equipment for up to five projects even before a Final Investment Decision (FID) is made, it has the potential to accelerate the timing of major equipment procurement by up to three years.” Accordingly, the analyst identified DOOSAN ENERBILITY, HyundaiEngineering&Construction, and KoreaElectricPower (KEPCO) as beneficiary stocks. He explained, “BHI Co., LTD. has consistently secured orders for nuclear power plant balance-of-plant (BOP) equipment from Korea Hydro & Nuclear Power Co. for domestic nuclear power projects, including Shin-Kori Units 3 and 4,” adding, “Although the BOP business currently accounts for only about 5% of total revenue, a meaningful revaluation could occur as visibility across the entire nuclear power value chain improves.”
“I’m heading home now.”When I sent a KakaoTalk message from outside my home, the artificial intelligence (AI) calculated my current location and the time it would take to get home. A moment later, I r…
Genome&Company(314130)is aiming for its third technology export deal, led by its next-generation antibody-drug conjugate (ADC) candidate, “GENA-120.” Although GENA-120 is still in the early clinical s…
(AI-generated image)
The “AI for Everyone” service, available free of charge to all citizens, will launch within the year. It will go beyond simple Q&A to become a one-stop, action-oriented servic…